Applied Therapeutics Q3 2025 Earnings Report

Applied Therapeutics EPS Results

• Actual EPS: -$0.13
• Consensus EPS: -$0.15
• Beat/Miss: Beat by +$0.02
• One Year Ago EPS: N/A

Applied Therapeutics Revenue Results

• Actual Revenue: $1.00 million
• Expected Revenue: $0.25 million
• Beat/Miss: Beat by +$750.00 thousand
• YoY Revenue Growth: N/A

Applied Therapeutics Announcement Details

• Quarter: Q3 2025
• Date: 11/13/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, November 13, 2025
• Conference Call Time: 7:00AM ET

Applied Therapeutics (NASDAQ:APLT), Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapies for genetically defined diseases. Its research strategy centers on structure-based drug design and proprietary screening technologies aimed at correcting underlying metabolic dysfunction in disorders characterized by enzyme deficiencies and toxic metabolite accumulation.

The company’s lead investigational candidate, AT-007, is an aldose reductase inhibitor engineered to cross the blood–brain barrier and is currently in clinical development for classic galactosemia. In addition to AT-007, Applied Therapeutics is advancing multiple programs targeting rare neurological and endocrine disorders, leveraging its platform to identify and optimize compounds that address high unmet medical needs in orphan and genetically defined patient populations.

Founded and headquartered in New York City, Applied Therapeutics has established collaborative partnerships with academic research institutions and contract research organizations throughout North America and Europe to support its preclinical and clinical operations. The company is guided by a leadership team with extensive experience in drug discovery, clinical development and regulatory affairs, positioning Applied Therapeutics to advance its pipeline toward key clinical milestones and potential regulatory approval.